These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 23234250)

  • 1. Improving lung cancer survival; time to move on.
    Heuvers ME; Hegmans JP; Stricker BH; Aerts JG
    BMC Pulm Med; 2012 Dec; 12():77. PubMed ID: 23234250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lung cancer: current therapies and new targeted treatments.
    Hirsch FR; Scagliotti GV; Mulshine JL; Kwon R; Curran WJ; Wu YL; Paz-Ares L
    Lancet; 2017 Jan; 389(10066):299-311. PubMed ID: 27574741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival of patients with advanced non-small-cell lung cancer at Ubon Ratchathani Cancer Center, Thailand.
    Srisam-Ang K; Podhipak A; Narksawat K; Supaattagorn P; Tipayamongkholgul M
    Southeast Asian J Trop Med Public Health; 2005 Jul; 36(4):994-1006. PubMed ID: 16295558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Conventional TNM and Novel TNMB Staging Systems for Non-Small Cell Lung Cancer.
    Haro GJ; Sheu B; Cook NR; Woodard GA; Mann MJ; Kratz JR
    JAMA Netw Open; 2019 Dec; 2(12):e1917062. PubMed ID: 31808928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
    Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
    J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward?
    Buffoni L; Vavalà T; Novello S
    Curr Treat Options Oncol; 2016 Oct; 17(10):54. PubMed ID: 27523606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer Progress and Priorities: Lung Cancer.
    Schabath MB; Cote ML
    Cancer Epidemiol Biomarkers Prev; 2019 Oct; 28(10):1563-1579. PubMed ID: 31575553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system.
    Arslan D; Bozcuk H; Gunduz S; Tural D; Tattli AM; Uysal M; Goksu SS; Bassorgun Cİ; Koral L; Coskun HS; Ozdogan M; Savas B
    Asian Pac J Cancer Prev; 2014; 15(6):2465-72. PubMed ID: 24761848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updates in Local-Regionally Advanced Non-Small Cell Lung Cancer.
    Tsao AS; Jolly S; Lee JM
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():553-562. PubMed ID: 31099691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving the prognosis for lung cancer patients.
    Clausen MM; Langer SW
    Acta Oncol; 2019 Aug; 58(8):1077-1078. PubMed ID: 31257968
    [No Abstract]   [Full Text] [Related]  

  • 12. Screening for patients with non-small cell lung cancer who could survive long term chemotherapy.
    Wu XY; Huang XE
    Asian Pac J Cancer Prev; 2015; 16(2):647-52. PubMed ID: 25684501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition.
    Tarhoni I; Wakefield CJ; Kollipara R; Fidler MJ; Batus M; Bonomi P; Borgia JA
    J Immunol Methods; 2021 Mar; 490():112956. PubMed ID: 33434603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stage I nonsmall cell lung carcinoma: analysis of survival and implications for screening.
    Dominioni L; Imperatori A; Rovera F; Ochetti A; Torrigiotti G; Paolucci M
    Cancer; 2000 Dec; 89(11 Suppl):2334-44. PubMed ID: 11147608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.
    Duma N; Santana-Davila R; Molina JR
    Mayo Clin Proc; 2019 Aug; 94(8):1623-1640. PubMed ID: 31378236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different efficacy of CT screening for lung cancer according to histological type: analysis of Japanese-smoker cases detected using a low-dose CT screen.
    Kondo R; Yoshida K; Kawakami S; Shiina T; Kurai M; Takasuna K; Yamamoto H; Koizumi T; Honda T; Kubo K
    Lung Cancer; 2011 Dec; 74(3):433-40. PubMed ID: 21663995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visceral pleura invasion by non-small cell lung cancer: an underrated bad prognostic factor.
    Manac'h D; Riquet M; Medioni J; Le Pimpec-Barthes F; Dujon A; Danel C
    Ann Thorac Surg; 2001 Apr; 71(4):1088-93. PubMed ID: 11308141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Lung cancer screening - where are we in 2013?].
    Prosch H; Mostbeck G
    Zentralbl Chir; 2013 Oct; 138 Suppl 1():S11-5. PubMed ID: 24150850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The treatment of non-small cell lung cancer: current perspectives and controversies, future directions.
    Bunn PA
    Semin Oncol; 1994 Jun; 21(3 Suppl 6):49-59. PubMed ID: 8052874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current methods in the diagnosis and therapy of lung cancer].
    Barchuk AS; Vagner RI; Lemekhov VG; Baĭkova VS; Gel'fond ML; Korolenko VO; Aristidov NI
    Vopr Onkol; 1997; 43(1):15-21. PubMed ID: 9133081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.